The World Cup Has a Ticket Problem & The First Ever Reverse-Aging Drug

This section explores the controversy around the upcoming World Cup, highlighting a surplus of unsold tickets despite FIFA's ticketing strategies aimed at maximizing revenue. Ticket resale prices have dropped, and many are still available, making the event less crowded and possibly affecting the stadium atmosphere negatively. The discussion considers how high prices and dynamic pricing might have backfired, risking the event's lively, authentic vibe, which is often diminished at major corporate events like the Super Bowl. The segment emphasizes the contrast in ticket prices between North America and Europe, with North America paying significantly more, partly due to FIFA's deliberate pricing strategies.

This part discusses the recent FDA approval for the first human clinical trial by a longevity startup, Life Biosciences, aimed at reversing aging. The trial involves injecting a patient with a compound to make old cells behave like younger ones, a process called cellular reprogramming. Despite small scale and limited scope (initially targeting glaucoma), the trial could pave the way for broader anti-aging applications. Prominent figures such as Elon Musk, Sam Altman, and Jeff Bezos are investing heavily in this field. The science hinges on partial reprogramming to avoid risks like cancer, using specific proteins (Yamannaka factors). Experts acknowledge both the promise and controversy surrounding longevity science.

This section celebrates the nearing completion of Gaudi’s famous Sagrada Família church, set to be inaugurated on its 100th death anniversary. The church's construction has been hampered by financial issues and destruction during the Spanish Civil War, but modern tools have helped verify Gaudi's intricate, nature-inspired designs. The discussion also covers local resentment towards overtourism and rising housing costs, which have led to protests and negative perceptions of foreign visitors. The intersection of cultural marvel and over-tourism underscores ongoing debates about balancing preservation with local quality of life.

This segment highlights the approval of BEMT, a new sunscreen ingredient in the US, offering better protection against UVB and UVA rays—something other countries have had for years. The US regulatory process is slower because sunscreens are classified as over-the-counter drugs, requiring extensive human trials. This has limited options and contributed to skepticism about sunscreen safety among Americans. The new ingredient, proven safe elsewhere, promises to enhance American sunscreen products once patents expire and more brands adopt it, addressing aesthetic concerns like white streaks from mineral sunscreens.

This part covers Anthropics' release of a more cautious AI model called Fable 5, designed with safeguards to mitigate risks, as companies like OpenAI advance their offerings. It also highlights NASA’s selection of astronauts for the Artemis III moon mission, which involves complex docking sequences with landers from SpaceX and Blue Origin—an operation fraught with recent technical setbacks. Finally, the hosts share personal lifestyle recommendations: playing an NBA team-building game to stay engaged and using high-fidelity earplugs to protect hearing during concerts.